2 news items
Guardant Health And Washington University To Present Study Highlighting Utility Of ctDNA To Address Racial Inequities In Use Of Targeted Therapies And Enrollment In Clinical Trials At 2024 ASCO Meeting
GH
3 Jun 24
Data from study using Guardant360® blood test show Black patients with PIK3CA mutations in advanced breast cancer were less likely
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
GH
3 Jun 24
from study using Guardant360® blood test show Black patients with PIK3CA mutations in advanced breast cancer were less likely than White patients
- Prev
- 1
- Next